Citius Pharmaceuticals to Participate in October 2026 Investor Conferences
PR Newswire•12/10/2026•08:30 ET
0
Key Highlights
- ➤Citius Pharma CEO Leonard Mazur to present at two October investor conferences
- ➤Citius Oncology launched LYMPHIR in December 2025 for eligible relapsed or refractory CTCL adults
- ➤Citius Pharma owns approximately 71% of Citius Oncology (CTOR)
- ➤LYMPHIR’s initial market currently exceeds $400 million, management estimates
- ➤Mino-Lok met primary and secondary endpoints in its Phase 3 trial
Expert Statements
Leonard Mazur, Chairman and Chief Executive Officer of Citius Pharmaceuticals
“Mr. Mazur will provide an overview of the Company's business and recent developments, including the ongoing commercialization of LYMPHIR(®) (denileukin diftitox-cxdl) by the Company's majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR).”
Citius Pharmaceuticals to Participate in October 2026 Investor Conferences PR Newswire
Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the 2026 Maxim Growth Summit and the ThinkEquity Conference
Get started
Create a free account to read the full story.